Richard Adcock - Dec 31, 2023 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role
CEO & President, Director
Signature
/s/ Jason Liljestrom, as Attorney-in-Fact
Stock symbol
IBRX
Transactions as of
Dec 31, 2023
Transactions value $
-$85,822
Form type
4
Date filed
1/3/2024, 09:40 PM
Previous filing
Feb 7, 2023
Next filing
Feb 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IBRX Common Stock Options Exercise $0 +34.5K +18.58% $0.00 220K Dec 31, 2023 Direct
transaction IBRX Common Stock Tax liability -$85.8K -17.1K -7.77% $5.02 203K Dec 31, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Restricted Stock Units Options Exercise $0 -34.5K -22.22% $0.00 121K Dec 31, 2023 Common Stock 34.5K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 31, 2023, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 29, 2023 was the settlement price used to calculate the shares withheld.
F2 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F3 Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.